Oryzon Genomics S.A.
ORYZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $101 | $97 | $128 | $151 |
| - Cash | $6 | $12 | $21 | $29 |
| + Debt | $11 | $14 | $17 | $14 |
| Enterprise Value | $107 | $99 | $124 | $136 |
| Revenue | $7 | $14 | $16 | $11 |
| % Growth | -48.1% | -9.6% | 47.9% | – |
| Gross Profit | $7 | $14 | $15 | $10 |
| % Margin | 95.9% | 98.3% | 97% | 93% |
| EBITDA | -$4 | -$4 | -$5 | -$7 |
| % Margin | -59.5% | -31.2% | -34.1% | -64.8% |
| Net Income | -$4 | -$3 | -$4 | -$5 |
| % Margin | -49.8% | -23.6% | -27% | -44.2% |
| EPS Diluted | -0.057 | -0.055 | -0.076 | -0.089 |
| % Growth | -2.7% | 27% | 15% | – |
| Operating Cash Flow | -$6 | -$1 | -$2 | -$4 |
| Capital Expenditures | -$8 | -$15 | -$14 | -$12 |
| Free Cash Flow | -$13 | -$15 | -$16 | -$15 |